Control of luteal relaxin release by prostaglandin F2 alpha: differences in the sow cycle and pregnancy.
The effect of an in vivo prostaglandin F2 alpha (PGF2 alpha) challenge in pregnant and cyclic sows was compared to determine whether PGF2 alpha-induced release of relaxin (RLX) from the corpus luteum (CL) in late pregnancy is also effective during the cycle. Ovarian venous RLX and progesterone were monitored by radioimmunoassay and RLX localized in the CL by immunohistochemistry. In Day 108 pregnant sows, infusion of PGF2 alpha (100 micrograms) into the ovarian artery resulted in an immediate and sustained rise in ovarian venous RLX with an initial decline in progesterone levels by 30 min which then returned to pretreatment levels. In Day 13 or 15 cyclic sows with functional corpora lutea (i.e., elevated progesterone), RLX was undetectable in ovarian venous blood after 100 micrograms of PGF2 alpha. Administration of PGF2 alpha via either the jugular vein or intramuscular route was also ineffective in releasing RLX from the CL of the cycle. The intensity of RLX immunostaining of the CL was similar in saline and PGF2 alpha-treated sows. These studies indicate that the control of RLX release from the sow CL differs in the estrous cycle and pregnancy.
Bagnell
C A
CA
Pacific Biomedical Research Center, University of Hawaii, Honolulu 96822.
Baker
N K
NK
McMurtry
J P
JP
Brocht
D M
DM
Lewis
G S
GS
D000818:Animals; D003338:Corpus Luteum / Q000187:drug effects / Q000378:metabolism; D015237:Dinoprost / Q000494:pharmacology*; D004971:Estrus / Q000187:drug effects*; D005260:Female; D007150:Immunohistochemistry; D011247:Pregnancy; D011270:Pregnancy, Animal / Q000187:drug effects*; D011374:Progesterone / Q000097:blood; D011863:Radioimmunoassay; D012065:Relaxin / Q000097:blood / Q000378:metabolism*; D013552:Swine / Q000378:metabolism*
D011374:Progesterone; D012065:Relaxin; D015237:Dinoprost